Skip to main content

Table 1 Baseline variables of 112 patients considered for lung biopsy from January of 2017 to December of 2019, stratified by MDD recommendation

From: Prospective cohort of cryobiopsy in interstitial lung diseases: a single center experience

Variable

Total

n = 112

No biopsy

n = 31

TBFB

n = 16

TBCB

n = 54

SLB

n = 11

p value

Age, median (p25–p75)

67 (61–73)

66 (60–74)

70 (58–74)

67 (61–73)

64 (59–68)

0.607

Male gender, n (%)

61 (55)

19 (61)

6 (38)

32 (59)

4 (36)

0.226

Any HP exposure*, n (%)

33 (30)

10 (32)

7 (44)

13 (24)

3 (27)

0.476

Positive HP panel, n (%)

23 (21)

5 (16)

7 (44)

8 (15)

3 (27)

0.655

CTD symptoms/signs**, n (%)

13 (12)

4 (13)

2 (13)

5 (9)

2 (18)

0.736

Any CTD serologies***, n (%)

20 (18)

5 (16)

2 (13)

11 (20)

2 (18)

0.928

Pulmonary function tests

      

 FVC pp, median (p25–p75)

71 (57–83)

69 (57–79)

69 (54–82)

73 (57–86)

71 (58–91)

0.621

 DLCO pp, median (p25–p75)

52 (42–60)

48 (35–59)

53 (42–57)

54 (45–61)

54 (40–59)

0.368

Radiology pattern, n (%)

     

< 0.001

 Definite UIP

9 (8)

5 (16)

1 (6)

2 (4)

1 (9)

 

 Probable UIP

44 (39)

12 (39)

4 (25)

27 (50)

1 (9)

 

 Indeterminate for UIP

12 (11)

0 (0)

3 (19)

9 (17)

0 (0)

 

 NSIP

17 (15)

8 (26)

1 (6)

5 (9)

3 (27)

 

 HP

8 (7)

3 (10)

3 (19)

1 (2)

1 (9)

 

 OP

1 (1)

0 (0)

0 (0)

0 (0)

1 (9)

 

 Smoking-related ILD

7 (6)

0 (0)

2 (13)

3 (6)

2 (18)

 

 Sarcoidosis

1 (1)

0 (0)

0 (0)

1 (2)

0 (0)

 

 Unclassifiable

6 (5)

0 (0)

0 (0)

6 (11)

0 (0)

 

 Other

7 (6)

3 (10)

()

0 (0)

2 (18)

 

Most likely diagnosis pre-biopsy, n (%)

     

< 0.001

 IPF

22 (20)

16 (52)

1 (6)

5 (9)

0 (0)

 

 NSIP

7 (6)

3 (10)

0 (0)

3 (6)

1 (9)

 

 CTD-related ILD

2 (2)

2 (7)

0 (0)

0 (0)

0 (0)

 

 HP

11 (10)

4 (13)

4 (25)

3 (6)

0 (0)

 

 Indeterminate

64 (57)

1 (3)

11 (69)

42 (78)

10 (90)

 

 Other

6 (5)

5 (16)

0 (0)

1 (2)

0 (0)

 
  1. MDD, multidisciplinary discussion; TBFB, transbronchial forceps biopsy; TBCB, transbronchial cryobiopsy; SLB, surgical lung biopsy; HP, hypersensitivity pneumonitis; OP, organizing pneumonia; CTD, connective tissue disease; FVC pp, forced vital capacity percent predicted; DLCO pp, diffusing capacity for carbon monoxide percent predicted; UIP, usual interstitial pneumonia; nonspecific interstitial pneumonia; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis
  2. *HP exposures: mold, birds, feathers, farm, hot tub, metalworking fluid; **CTD symptoms/signs: mechanic’s hands, digital ulcers, arthritis or morning stiffness, palmar telangiectasia, Raynaud’s phenomenon, digital edema, Gottron’s sign; ***CTD serologies: ANA, anti-centromere, rheumatoid factor, anti-CCP, anti-ds-dna, anti-SSA, anti-SSB, anti-RNP, anti-Smith, anti-Scl-70, myositis antibodies